|
Volumn 114, Issue 3, 2001, Pages 734-735
|
Advanced-stage, chemorefractory lymphocyte-predominant Hodgkin's disease: Long-term follow-up of allografting and monoclonal antibody therapy [3]
a a a |
Author keywords
Allogeneic transplantation; Anti CD20; Chemorefractory; Lymphocyte predominant Hodgkin's disease; Rituximab
|
Indexed keywords
BLEOMYCIN;
CARMUSTINE;
CHLORAMBUCIL;
CYCLOSPORIN A;
CYTARABINE;
DOXORUBICIN;
EPIRUBICIN;
ETOPOSIDE;
IFOSFAMIDE;
MELPHALAN;
METHOTREXATE;
MONOCLONAL ANTIBODY;
PREDNISOLONE;
PROCARBAZINE;
RITUXIMAB;
THYMOCYTE ANTIBODY;
VINBLASTINE;
VINCRISTINE;
ADULT;
ALLOGRAFT;
CASE REPORT;
CHIMERA;
CLINICAL FEATURE;
CONTROLLED STUDY;
DONOR;
FOLLOW UP;
GRAFT VERSUS HOST REACTION;
HEMATOPOIESIS;
HODGKIN DISEASE;
HUMAN;
LETTER;
LONG TERM CARE;
MALE;
PERIPHERAL BLOOD STEM CELL;
PRIORITY JOURNAL;
REMISSION;
TREATMENT OUTCOME;
ADULT;
ANTIBODIES, MONOCLONAL;
HEMATOPOIETIC STEM CELL TRANSPLANTATION;
HODGKIN DISEASE;
HUMANS;
MALE;
MIDDLE AGED;
TRANSPLANTATION, HOMOLOGOUS;
|
EID: 0034800377
PISSN: 00071048
EISSN: None
Source Type: Journal
DOI: None Document Type: Letter |
Times cited : (10)
|
References (7)
|